Moreover, WKYMVm treatment has been shown to promote differentiation of fibroblasts to myofibroblasts and matrix deposition in vitro, suggesting a deteriorating effect of Fpr2 activation in scleroderma. The gene discussed is FPR2; the disease is scleroderma.